Back to Authors

Hartnett, M. Elizabeth

https://orcid.org/0000-0002-7270-5670

A5136832098 | I4210161109

Mayo Clinic

Smith-Kettlewell Eye Research Institute

Citations 5

Ocular and Systemic Findings in COL2A1 and COL11A1 Stickler Syndrome

American Journal of Medical Genetics Part A | July 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajmg.a.70244 | PMID 42458851

ABSTRACT Stickler syndrome is most commonly caused by variants in COL2A1 and COL11A1 genes. The purpose of this study was to describe genetic variants and phenotypes in COL2A1 and COL11A1 Stickler syndrome. We performed a retrospective genotype–phenotype evaluation of COL2A1 and COL11A1 Stickler syndrome subjects. Thirty‐two subjects with COL2A1 and 13 subjects with COL11A1 Stickler syndrome were last seen in clinic at a mean age of 17.2 ± 13.1 and 12.6 ± 3.8 years, respectively ( p = 0.08). We found that 50% of COL2A1 subjects had lattice degeneration, whereas 8% of the COL11A1 subjects had lattice degeneration ( p = 0.015). The most common type of variant for COL2A1 Stickler syndrome was a premature termination codon (12 out of 18 families, 67%); and the most common types of variants for COL11A1 Stickler syndrome were glycine missense variants (4 out of 10 families, 40%) and splice site variants (4 out of 10 families, 40%). There was a higher rate of lattice degeneration in COL2A1 patients compared with COL11A1 patients, a finding that could be influenced by a trend towards older age at last follow‐up in the COL2A1 group.
Streamlining the diagnostic and management pathways of patients with retinitis pigmentosa

Ophthalmic Genetics | March 5, 2026 | Volume: 47 | Issue: 3 | Pages: 221-226

10.1080/13816810.2025.2604027 | PMID 41730765

Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity

JAMA Ophthalmology | April 23, 2020 | Volume: 138 | Issue: 6 | Pages: 698

10.1001/jamaophthalmol.2020.0334 | PMID 32324197

Stanniocalcin-1 is a Modifier of Oxygen-Induced Retinopathy Severity

Current Eye Research | July 17, 2019 | Volume: 45 | Issue: 1 | Pages: 46-51

10.1080/02713683.2019.1645184 | PMID 31314602

Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity

JAMA Ophthalmology | April 27, 2017 | Volume: 135 | Issue: 6 | Pages: 654

10.1001/jamaophthalmol.2017.1055 | PMID 28448664